SIM0270, a new monotherapy treatment for advanced breast cancer, shows promising clinical activity and a manageable safety profile in a phase 1 clinical trial. Read More ›

SIM0270, a novel selective estrogen receptor degrader, combined with everolimus shows preliminary efficacy with a high rate of treatment-emergent adverse events at the recommended dose in treating patients with advanced breast cancer. Read More ›

Racial disparities are evident in the treatment and outcomes for patients with hormone receptor–positive/HER2-negative metastatic breast cancer in the United States. Read More ›

The ZEST study explored the potential of niraparib in treating early-stage breast cancer patients with detectable ctDNA, paving the way for future research on personalized treatment strategies based on ctDNA detection. Read More ›

Final analysis of the DAWNA-2 trial confirms the addition of dalpiciclib to endocrine therapy significantly improves progression-free survival in patients with hormone receptor–positive/HER2-negative advanced breast cancer. Read More ›

While artificial intelligence offers promising applications in healthcare, such as generating clinical summaries and estimating risks, its integration is hindered by limitations in EHR systems and the need for further model development Read More ›

A new study highlights the potential of serial liquid biopsies to monitor treatment response and uncover dynamic genomic changes in patients with metastatic breast cancer. Read More ›

Patients with metastatic breast cancer prefer oral endocrine therapy because of convenience, while healthcare providers recognize the benefits of oral and intramuscular options. Read More ›

Imlunestrant, a novel oral SERD, demonstrates promising efficacy and safety in a phase 3 trial for advanced breast cancer patients. Read More ›

Early results from the SERENA-1 trial show camizestrant combined with ribociclib may be safe and effective for treating estrogen receptor–positive/HER2-negative advanced breast cancer. Read More ›